Form 4: Passage Bio Director Maxine Gowen Granted Over 200,000 Stock Options

Passage Bio, Inc. Director Maxine Gowen was granted 201,857 stock options with an exercise price of $0.3598, vesting on the earlier of the one-year anniversary of the grant or the 2026 Annual Meeting.

Summary

• Maxine Gowen, a Director of Passage BIO, Inc. (PASG), was granted 201,857 stock options on May 28, 2025.
• The exercise price for these options is $0.3598 per share.
• The options are for Common Stock, with each option representing the right to buy one share.
• The options will vest in full on the earlier of May 28, 2026 (one-year anniversary of the grant date) or the date of the issuer's 2026 Annual Meeting of stockholders, contingent on Ms. Gowen's continuous service.
• The options have an expiration date of May 28, 2035.
• Following this transaction, Ms. Gowen beneficially owns 201,857 derivative securities (stock options).
• A Limited Power of Attorney was executed on May 30, 2025, appointing Kathleen Borthwick, Edgar Cale, and William Chou as attorneys-in-fact for Section 16 filings on behalf of Maxine Gowen.

Sentiment

Score: 6

Explanation: The document reports a standard compensation event (stock option grant) to a director, which is generally a neutral to slightly positive signal as it aligns interests, but does not indicate significant operational or financial news.

Positives

• The grant of 201,857 stock options to Director Maxine Gowen aligns her interests with long-term shareholder value, as the options gain value if the stock price increases above the exercise price of $0.3598.
• The vesting schedule encourages continued service and commitment from a key board member.

Negatives

• The issuance of stock options, if exercised, could lead to dilution of existing shareholders' equity, although the impact from this single grant is likely minimal.

Risks

• The value of the stock options is contingent on the future performance of Passage Bio's common stock; if the stock price does not rise above the exercise price of $0.3598, the options may not be profitable.
• The vesting of options is subject to the reporting person's continuous service to the issuer, meaning the options could be forfeited if service is terminated before vesting.

Future Outlook

The document primarily details an insider transaction and does not provide forward-looking statements regarding the company's financial performance or strategic direction, beyond the vesting schedule of the granted options.

Industry Context

This Form 4 filing details a routine equity compensation grant to a director, which is a common practice across industries, including biotechnology, to align executive and board member incentives with shareholder interests. It does not provide broader industry trends or competitive analysis.

Corporate Governance

Related Party Transactions

• The grant of stock options to Maxine Gowen, a Director of Passage Bio, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: Potential minor dilution if options are exercised, but also potential alignment of director's interests with long-term stock price appreciation.
• Employees: No direct impact mentioned, but standard compensation practices can influence overall company culture and retention.

Next Steps

• The stock options are subject to vesting on the earlier of May 28, 2026, or the date of the issuer's 2026 Annual Meeting of stockholders, contingent on continuous service.
• The options will expire on May 28, 2035, if not exercised.

Key Dates

Keywords

Passage Bio, PASG, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Maxine Gowen, Biotechnology, Pharmaceuticals